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Abstract 
Autoimmune and paraneoplastic movement disorders are rare in childhood. Diagnosis often relies on clinical mani-
festations and clinicians’ recognition. A 22-month-old girl at onset of opsoclonus-myoclonus syndrome (OMS) was fol-
lowed for 8 years. Adenovirus (type C subtype 3) infection coincided with manifestation. Data on treatment, imaging 
and follow-up are provided. In the spinal fluid, elevated anti-rubella antibodies and oligoclonal bands were detected. 
An autoimmune process affecting mainly cerebellar neurons was revealed immunohistochemically. Moderately 
intense long-term immunosuppressive therapy resulted in a favorable clinical outcome. A video demonstrated severe 
OMS manifestations at onset, followed by nearly complete recovery after treatment. We describe the association of 
a parainfectious OMS and adenovirus infection; laboratory results indicate a non-specific humoral process affecting 
mainly cerebellar neurons. Our video documentation will aid to recognize this rare movement disorder and to initiate 
early treatment.
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Background
The spectrum of movement disorders in childhood is 
diverse. Diagnosis remains often descriptive. Opso-
clonus-myoclonus-(ataxia) syndrome (OMS), or danc-
ing-eyes syndrome, is a rare encephalopathy, seen mainly 
in infancy with an estimated incidence per year of 0.18 
per million total population (Pang et  al. 2010). OMS is 
characterized by jerking conjugated bulbar movements, 
ataxia with myoclonus and psychiatric symptoms such as 
behavioral change. Most adult cases are of paraneoplastic 
origin. In about 50 % of children, OMS is associated with 
neuroblastoma, whereas the other cases are triggered 
by infections. OMS is characterized as an autoimmune 
disease with B- and T-cell activation. Autoantibodies 
binding to neuronal proteins have been described (Blaes 
et al. 2005; Pranzatelli et al. 2004). Empirical therapy con-
sists of immunosuppressive agents with differing treat-
ment strategies (Denne et  al. 2006; Rostasy et  al. 2006). 
Initiation of treatment relies on the recognition of the 
clinical picture. Misdiagnoses and a mean delay in cor-
rect diagnosis of 11  weeks indicate insufficient knowl-
edge of this recognizable movement disorder among 
pediatricians (Tate et al. 2005).
Case description
A formerly healthy 22-month-old girl presented for pro-
gressive gait disturbance and jitteriness since the day 
before. During the preceding week she was seen by her 
pediatrician for a febrile upper respiratory tract infection. 
Clinical investigation revealed mild signs of upper respir-
atory tract infection. Neurological examination showed 
a constant tremor and mild gait ataxia. Force, sensi-
bility and deep tendon reflexes were normal, whereas 
pyramidal signs were absent. Magnetic resonance imag-
ing (MRI) of the brain and electroencephalography 
(EEG) were performed on the first day and repeated 
after 2 weeks showing no pathological findings. Cerebro-
spinal fluid (CSF) analysis performed on day 1 revealed 
12 leucocytes/µl with 83  % lymphocytes and intrathe-
cal production of IgM and IgA antibodies. Normal val-
ues were obtained for glucose, lactate and protein. Due 
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to contact with chickenpox 10 days prior to admittance 
and assumed cerebellitis, she was treated with acyclovir 
over 10  days. During the following 2  weeks the clinical 
picture deteriorated. She developed constant myoclonic 
jerks, severe ataxia, bobbing eye movements and extreme 
irritability with aggressive behavior. She was able neither 
to sit nor to stand, and hyperkinetic movements persisted 
during sleep (see Additional file 1: Video).
The clinical picture led to the diagnosis of opsoclonus-
myoclonus syndrome. No neuroblastoma was found by 
abdominal ultrasound, chest X-ray and meta-iodo-ben-
zylguanidine scintigraphy. Due to positive polymerase 
chain reaction (PCR) for adenovirus type C subtype 3 
in serum (2800 copies/ml) on day 3 after admittance, a 
parainfectious OMS was suspected. Repeated CSF analy-
sis on day 24 showed persisting inflammatory changes, 
including 6 leucocytes/µl, positive oligoclonal bands and 
elevated neopterin-levels. Virological analysis revealed an 
elevated specific antibody index (ASI) of 5.2 for mumps 
IgG. Serum antibody testing and PCR ruled out acute 
infection with mumps, herpes simplex, influenza, parain-
fluenza, measles, human herpes virus type 6, varicella-
zoster and Epstein-Barr virus.
Serum from the patient was applied to indirect immu-
nofluorescence labeling and stained cerebellar neu-
rons (Fig.  1). In parallel, attempts based on onconeural 
autoantibodies, recognizing the markers Hu, Yo or Ri, 
and antibodies directed against gangliosides produced no 
immunolabeling of the same tissue.
Ten weeks after patient’s admittance, immunosuppres-
sive therapy started with methylprednisolone (20 mg/kg) 
over 5 days every month; after 3 months, the therapy was 
extended with adrenocorticotropic hormone (ACTH, 
60 units three times monthly) and intravenous immuno 
globulin (IVIG, 1  g/kg every second month) for 1  year. 
Along with the initiation of this therapy, the neurological 
status improved.
Due to persisting tremor and irritability, therapy was 
switched to oral dexamethasone (12  mg each on 3  days 
monthly) after 1  year and subsequently tapered over 
3  years. Overall, the immunosuppressive therapy lasted 
50 months.
The patient is now 12  years-old and shows an age-
appropriate intelligence, visual-spatial performance and 
motor performance (Kaufman assessment battery, devel-
opmental test of visual perception 2, motoric test for 
children) and attends a normal primary school. She is 
infrequently showing slight myoclonic and ataxic move-
ments, worsened during febrile illness. Brain MRI after 
5 years was indicative of slight cerebellar atrophy (Fig. 2).
Discussion and evaluation
Our report illustrates the course of a severe case of OMS. 
To our knowledge, this is the first patient with an asso-
ciated adenoviral infection, which was demonstrated by 
positive PCR during onset of first symptoms. If occult 
neuroblastoma had been present in this patient it pre-
sumably regressed spontaneously. Outcome of OMS is 
often associated with long-term neurological morbidity 
and cognitive problems (Klein et al. 2007); however, the 
long-term but moderately intense immunosuppressive 
treatment in our patient led to nearly complete recov-
ery with age appropriate cognitive function. Adenoviral 
infection is a likely cause of OMS in our patient. We could 
prove the hypothesis of an immune-mediated response 
to cerebellar neurons by immunohistochemistry, which 
suggests that OMS is affecting cerebellar neurons. Serum 
antibodies of our patient stained cerebellar neurons with 
probably different antigens, as there was positive staining 
of Purkinje cells, granule cells and neurons of deep cer-
ebellar nuclei. Immunofluorescence labeling predomi-
nantly revealed membrane-associated antigens. Despite 
the lack of a control group, this observation is in line with 
previous studies, which showed similar immunostaining 
patterns, but failed to identify defined antigens (Blaes 
et al. 2005; Connolly et al. 1997).
Another fact confirming a predominant cerebel-
lar inflammation is the brain MRI on 5-year follow-up 
with mild signs of cerebellar atrophy—a finding previ-
ously reported by Hayward and co-workers (Hayward 
et  al. 2001). Apart from a specific immune response to 
cerebellar neurons, the patient displayed a non-specific 
humoral immune response in the CNS with up-regu-
lation of vaccination titers, as indicated by an elevated 
ASI of 5.2 for anti-mumps IgG and oligoclonal bands 
in CSF. The patient had no history of previous mumps 
infection and was vaccinated (MMR Triplovax, Sanofi-
Pasteur-MSD) 4  months prior to the onset of OMS, 
which makes a causal relationship unlikely. Another 
patient with OMS was characterized by elevated anti-
rubella-antibodies in CSF, suggesting rubella infection as 
etiologic factor, but evidence of infection was not given 
(Denne et  al. 2006). It is likely that in OMS a non-spe-
cific immune response occurs in the CNS comparable to 
other immune-mediated inflammatory diseases of the 
CNS (Jarius et al. 2009). The mean delay of 17 weeks in 
initiation of treatment is unacceptably long (Tate et  al. 
2005). Our video-documented study will help child neu-
rologists to recognize this treatable movement disorder 
and to shorten the time to establish immunosuppressive 
therapy.
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Conclusions
Our case study illustrates severe symptoms of OMS and 
the favorable outcome after long-term immunosuppressive 
treatment. Further studies are needed for the identification 
of specific antibodies as biomarkers and for the recogni-
tion of the disease-specific cerebellar antigens in OMS.
Fig. 1 Double immunofluorescence labeling of cerebellar frozen sections from a human autoptic case. Binding sites for autoantibodies from the 
patient (green) and astroglial or neuronal markers (red) are concomitantly revealed by confocal laser-scanning microscopy. Autoantigens are stained 
by patient’s serum (1:20) and carbocyanine (Cy) 2-conjugated anti-human IgG + IgM, while astroglia and neurons are visualized by appropriate Cy3-
coupled secondary antibodies. a At lower magnification, the cerebellar subcortex displays layers of granular cells immunoreactive for the patient’s 
serum—clearly distinguishable from immunoreactivity for rabbit-anti-glial fibrillary acidic protein (GFAP; Dakocytomation; 1:1000). b At higher 
magnification, autoantibodies bind cells of deep cerebellar nuclei lacking GFAP immunolabeling. c In the cerebellar cortex, Purkinje cells are stained 
by patient’s serum while rabbit-anti-S100β (Swant; 1:500) predominantly demonstrates protoplasmic astroglia. d Immunodecoration of probably 
neuronal surface antigens with patient’s serum is located apart from labeling achieved with mouse-anti-neuronal nuclei (NeuN; Millipore; 1:100) in 
the layer of deep cerebellar neurons. Scale bars in a, c = 200 µm, in b, d = 50 µm
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The patient and her parents gave written informed con-
sent and agreement to the publication of this report.
Authors’ contributions
Dr SS wrote the first draft of the manuscript. Prof AM wrote parts of the manu-
script and together with Dr MKB took part in the clinical care for the patient, 
including treatment strategies. Prof UGL performed the virological analyses. 
Prof WH was responsible for the radiological investigations of the patient. 
Prof WH conducted the preparation of sample tissue, performed immuno-
fluorescence labeling and wrote parts of the manuscript. Dr JG carried out 
confocal laser-scanning microscopy. All authors read and approved the final 
manuscript.
Author details
1 Department of Women and Child Health, Hospital for Children and Adoles-
cents, University Hospitals, University of Leipzig, Liebigstr 20a, 04103 Leipzig, 
Germany. 2 Paul Flechsig Institute for Brain Research, University of Leipzig, 
Liebigstr. 19, 04103 Leipzig, Germany. 3 Institute of Virology, University of Leip-
zig, Johannisallee 30, 04103 Leipzig, Germany. 4 Section Paediatric Radiology, 
Department of Imaging and Radiotherapy, University of Leipzig, 04103 Leipzig, 
Germany. 
Acknowledgements
Autoptic human cerebellar tissue was generously provided by Dr. Thomas 
Arendt. The authors thank Ms Hildegard Gruschka for sectioning of the tissue 
sample. We acknowledge support from the German Research Foundation 
(DFG) and Universität Leipzig within the program of Open Access Publishing. 
The patient and her family are gratefully acknowledged for kindly providing 
the video.
Competing interests
The authors declare that they have no competing interests.
Additional file
Additional file 1. Video showing patient before onset of disease (First 
Part), 6 weeks after onset with severe ataxic and myoclonic hyperkinetic 
movements and opsoclonus (Second Part) and at the age of 8 years 
demonstrating favorable outcome (Third Part).
Received: 7 August 2015   Accepted: 12 October 2015
References
Blaes F, Fühlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, 
Kaps M, Preissner KT (2005) Surface-binding autoantibodies to cerebellar 
neurons in opsoclonus syndrome. Ann Neurol 58:313–317
Connolly AM, Pestronk A, Mehta S, Pranzatelli MR 3rd, Noetzel MJ (1997) Serum 
autoantibodies in childhood opsoclonus-myoclonus syndrome: an analy-
sis of antigenic targets in neural tissues. J Pediatr 130:878–884
Denne C, Kleines M, Scheithauer S, Heimann G, Häusler M (2006) Methotrex-
ate: a new treatment in opsoclonus-myoclonus syndrome. J Pediatr 
Neurol. 4:183–185
Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, Crit-
tenden M, Matthay KK (2001) Long-term neurobehavioral outcomes 
in children with neuroblastoma and opsoclonus-myoclonus-ataxia 
syndrome: relationship to MRI findings and anti-neuronal antibodies. J 
Pediatr 139:552–559
Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Voltz R (2009) The intrathe-
cal, polyspecific antiviral immune response: specific for MS or a general 
marker of CNS autoimmunity? J Neurol Sci 280:98–100
Klein A, Schmitt B, Boltshauser E (2007) Long-term outcome of ten children 
with opsoclonus-myoclonus syndrome. Eur J Pediatr 166:359–363
Pang KK, de Sousa C, Lang B, Pike MG (2010) A prospective study of the 
presentation and management of dancing eye syndrome/opsoclonus-
myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 
14:156–161
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro 
MA, Parke JT, Stumpf DA, Verhulst SJ (2004) B- and T-cell markers in 
opsoclonus-myoclonus syndrome: immunophenotyping of CSF lympho-
cytes. Neurology 62:1526–1532
Rostasy K, Wilken B, Baumann M, Müller-Deile K, Bieber I, Gärtner J, Möller P, 
Angelini P, Hero B (2006) High dose pulsatile dexamethasone therapy 
in children with opsoclonus-myoclonus syndrome. Neuropediatrics 
37:291–295
Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ (2005) Neuroepidemiologic 
trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J 
Pediatr Oncol Nurs 22:8–19
Fig. 2 Sagittal T2-weighted cranial magnetic resonance images at onset of opsoclonus-myoclonus syndrome (a) and 5 years later (b), showing mild 
cerebellar atrophy with widened sulci and extracerebellar spaces
